These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Glucagon is the key factor in the development of diabetes. Lee YH; Wang MY; Yu XX; Unger RH Diabetologia; 2016 Jul; 59(7):1372-1375. PubMed ID: 27115412 [TBL] [Abstract][Full Text] [Related]
4. The role of leptin in diabetes: metabolic effects. Meek TH; Morton GJ Diabetologia; 2016 May; 59(5):928-32. PubMed ID: 26969486 [TBL] [Abstract][Full Text] [Related]
5. Renaissance of leptin for obesity therapy. Quarta C; Sánchez-Garrido MA; Tschöp MH; Clemmensen C Diabetologia; 2016 May; 59(5):920-7. PubMed ID: 26983921 [TBL] [Abstract][Full Text] [Related]
6. Hepatic glucose and lipid metabolism. Jones JG Diabetologia; 2016 Jun; 59(6):1098-103. PubMed ID: 27048250 [TBL] [Abstract][Full Text] [Related]
7. Multiple benefits of targeting inflammation in the treatment of type 2 diabetes. Donath MY Diabetologia; 2016 Apr; 59(4):679-82. PubMed ID: 26868493 [TBL] [Abstract][Full Text] [Related]
8. Is it worth treating gestational diabetes: if so, when and how? Vääräsmäki M Diabetologia; 2016 Jul; 59(7):1391-1395. PubMed ID: 27168136 [TBL] [Abstract][Full Text] [Related]
9. Mitochondrial network regulation and its potential interference with inflammatory signals in pancreatic beta cells. Baltrusch S Diabetologia; 2016 Apr; 59(4):683-7. PubMed ID: 26873508 [TBL] [Abstract][Full Text] [Related]
10. Pleotropic effects of leptin to reverse insulin resistance and diabetic ketoacidosis. Perry RJ; Petersen KF; Shulman GI Diabetologia; 2016 May; 59(5):933-7. PubMed ID: 26961503 [TBL] [Abstract][Full Text] [Related]
11. MST1: a promising therapeutic target to restore functional beta cell mass in diabetes. Ardestani A; Maedler K Diabetologia; 2016 Sep; 59(9):1843-9. PubMed ID: 27053234 [TBL] [Abstract][Full Text] [Related]
12. Gestational diabetes mellitus and long-term consequences for mother and offspring: a view from Denmark. Damm P; Houshmand-Oeregaard A; Kelstrup L; Lauenborg J; Mathiesen ER; Clausen TD Diabetologia; 2016 Jul; 59(7):1396-1399. PubMed ID: 27174368 [TBL] [Abstract][Full Text] [Related]
13. G protein-coupled receptors as new therapeutic targets for type 2 diabetes. Reimann F; Gribble FM Diabetologia; 2016 Feb; 59(2):229-33. PubMed ID: 26661410 [TBL] [Abstract][Full Text] [Related]
14. Glucagon signalling in the dorsal vagal complex is sufficient and necessary for high-protein feeding to regulate glucose homeostasis in vivo. LaPierre MP; Abraham MA; Yue JT; Filippi BM; Lam TK EMBO Rep; 2015 Oct; 16(10):1299-307. PubMed ID: 26290496 [TBL] [Abstract][Full Text] [Related]
15. Treatment of gastrointestinal autonomic neuropathy. Törnblom H Diabetologia; 2016 Mar; 59(3):409-13. PubMed ID: 26634570 [TBL] [Abstract][Full Text] [Related]
16. Cocaine- and amphetamine-regulated transcript: a novel regulator of energy homeostasis expressed in a subpopulation of pancreatic islet cells. Gilon P Diabetologia; 2016 Sep; 59(9):1855-9. PubMed ID: 27421727 [TBL] [Abstract][Full Text] [Related]
17. Lipids and immunoinflammatory pathways of beta cell destruction. Imai Y; Dobrian AD; Morris MA; Taylor-Fishwick DA; Nadler JL Diabetologia; 2016 Apr; 59(4):673-8. PubMed ID: 26868492 [TBL] [Abstract][Full Text] [Related]
19. Islet α cells and glucagon--critical regulators of energy homeostasis. Campbell JE; Drucker DJ Nat Rev Endocrinol; 2015 Jun; 11(6):329-38. PubMed ID: 25850661 [TBL] [Abstract][Full Text] [Related]
20. Key elements of metabolomics in the study of biomarkers of diabetes. Adamski J Diabetologia; 2016 Dec; 59(12):2497-2502. PubMed ID: 27714446 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]